Cervomed Stock Today
| CRVO Stock | 6.44 0.65 11.23% |
PerformanceGood
| Odds Of DistressBelow Average
|
CervoMed is selling at 6.44 as of the 16th of March 2025; that is 11.23% up since the beginning of the trading day. The stock's open price was 5.79. CervoMed has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of January 2016 | Category Healthcare | Classification Health Care |
CervoMed is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 8.25 M outstanding shares of which 966.03 K shares are currently shorted by private and institutional investors with about 10.62 trading days to cover. More on CervoMed
Moving against CervoMed Stock
CervoMed Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, CoFounder | John MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CervoMed can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CervoMed's financial leverage. It provides some insight into what part of CervoMed's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CervoMed (CRVO) is traded on NASDAQ Exchange in USA. It is located in 20 Park Plaza, Boston, MA, United States, 02116 and employs 8 people. CervoMed is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.15 M. CervoMed conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.25 M outstanding shares of which 966.03 K shares are currently shorted by private and institutional investors with about 10.62 trading days to cover.
CervoMed generates negative cash flow from operations
Check CervoMed Probability Of Bankruptcy
Ownership AllocationThe market capitalization of CervoMed is USD53.15 Million. CervoMed retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check CervoMed Ownership Details
CervoMed Historical Income Statement
CervoMed Stock Against Markets
CervoMed Corporate Management
| Mark Rosch | SVP Management | Profile | |
| Claudia MD | Senior Science | Profile | |
| John Tanner | Chief Officer | Profile | |
| William JD | General Secretary | Profile | |
| Kelly MHA | Senior Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CervoMed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in CervoMed Stock, please use our How to Invest in CervoMed guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CervoMed. If investors know CervoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CervoMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Revenue Per Share | Quarterly Revenue Growth 0.271 | Return On Assets | Return On Equity |
The market value of CervoMed is measured differently than its book value, which is the value of CervoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CervoMed's value that differs from its market value or its book value, called intrinsic value, which is CervoMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CervoMed's market value can be influenced by many factors that don't directly affect CervoMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CervoMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if CervoMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CervoMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.